Article
Oncology
Kirsten Jorgensen, Alexander Melamed, Chi-Fang Wu, Roni Nitecki, Rene Pareja, Anna Fagotti, John O. Schorge, Pedro T. Ramirez, Jose Alejandro Rauh -Hain
Summary: This study aimed to assess the outcomes of interval debulking surgery (IDS) after neoadjuvant chemotherapy via minimally invasive surgery (MIS) compared with laparotomy in patients with advanced epithelial ovarian cancer. The study found that patients who underwent IDS with MIS had similar overall survival and decreased morbidity compared with those who underwent laparotomy.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Mireia Crispin-Ortuzar, Ramona Woitek, Marika A. V. Reinius, Elizabeth Moore, Lucian Beer, Vlad Bura, Leonardo Rundo, Cathal McCague, Stephan Ursprung, Lorena Escudero Sanchez, Paula Martin-Gonzalez, Florent Mouliere, Dineika Chandrananda, James Morris, Teodora Goranova, Anna M. Piskorz, Naveena Singh, Anju Sahdev, Roxana Pintican, Marta Zerunian, Nitzan Rosenfeld, Helen Addley, Mercedes Jimenez-Linan, Florian Markowetz, Evis Sala, James D. Brenton
Summary: High grade serous ovarian carcinoma (HGSOC) is a highly heterogeneous disease with difficulties in predicting response to chemotherapy. This study presents a framework that integrates baseline clinical data, blood-based markers, and radiomic biomarkers to predict the response of patients to chemotherapy. The results show that incorporating radiomics data into the model significantly improves prediction accuracy.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Minjun He, Yuerong Lai, Hongyu Peng, Chongjie Tong
Summary: The therapeutic value of lymphadenectomy in patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy followed by interval debulking surgery remains unclear. Residual disease >=1cm and elevated CA125 levels after 3 cycles of adjuvant chemotherapy were identified as negative predictors for overall survival.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Xinyue Zhang, Jie Yang, Yang Xiang, Lingya Pan, Ming Wu, Dongyan Cao, Jiaxin Yang
Summary: This retrospective cohort analysis compared surgery and survival outcomes between neoadjuvant chemotherapy and primary debulking surgery in patients with advanced ovarian yolk sac tumor. The study found that after neoadjuvant chemotherapy, the surgical conditions of patients were improved, and there was no statistical difference in 3-year disease-free survival and overall survival between the two groups. Patients who underwent interval debulking surgery after neoadjuvant chemotherapy had less blood loss, transfusion volume, and peri-operative complications compared with those who underwent primary debulking surgery.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Article
Oncology
Angeliki Andrikopoulou, Charalampos Theofanakis, Christos Markellos, Maria Kaparelou, Konstantinos Koutsoukos, Kleoniki Apostolidou, Nikolaos Thomakos, Dimitrios Haidopoulos, Alexandros Rodolakis, Meletios-Athanasios Dimopoulos, Flora Zagouri, Michalis Liontos
Summary: The optimal time interval between neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) in high-grade serous ovarian carcinoma (HGSC) is unclear. A retrospective study was conducted on HGSC patients who underwent NACT followed by IDS in a 15-year period. The study found that performing IDS within four weeks after NACT was associated with better survival outcomes. Multivariate analysis showed that a short time interval (<4 weeks) from NACT to IDS was an independent factor of both PFS and OS.
Article
Oncology
Shoji Nagao, Jun Tamura, Takashi Shibutani, Maiko Miwa, Tomoyasu Kato, Ayumi Shikama, Yuji Takei, Natsuko Kamiya, Naoki Inoue, Kazuto Nakamura, Aya Inoue, Koji Yamamoto, Keiichi Fujiwara, Mitsuaki Suzuki
Summary: This study evaluated the status and effectiveness of using neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS) in the treatment of advanced epithelial ovarian cancer in Japan. The results showed that NAC followed by IDS did not improve survival, and in patients with FIGO stage IIIC, NAC may be associated with a shorter overall survival.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Zheng Feng, Hao Wen, Ruimin Li, Shuai Liu, Yi Fu, Xiaojun Chen, Rui Bi, Xingzhu Ju, Xiaohua Wu
Summary: This study compared the survival rates of ovarian cancer patients treated with PDS and NACT, finding that the PDS group had a longer PFS than the NACT group. Among NACT patients, those with residual disease had the worst PFS performance.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Stefano Uccella, Mariachiara Bosco, Luca Mezzetto, Simone Garzon, Veronica Maggi, Simone Giacopuzzi, Alessandro Antonelli, Lucia Pinali, Pier Carlo Zorzato, Anna Festi, Enrico Polati, Stefania Montemezzi, Giovanni De Manzoni, Massimo P. Franchi, Gian Franco Veraldi
Summary: This study reviewed the literature on oncovascular surgery in ovarian cancer and reported the cases performed at their institution. The results showed that preoperative identification of vascular involvement was crucial in major vessel resection for ovarian cancer. The study also found a high rate of postoperative complications in patients who underwent vascular resection. The authors emphasized the importance of a multidisciplinary approach and customized care in oncovascular surgery for ovarian cancer.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Oncology
Wei Wang, Min Gao, Xiaoting Li, Hong Zheng, Yunong Gao
Summary: The study found that neoadjuvant chemotherapy combined with intraperitoneal chemotherapy after interval debulking surgery could improve the progression-free survival of patients with advanced epithelial ovarian cancer compared to intravenous chemotherapy, with no significant differences in toxicity.
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY
(2022)
Article
Oncology
Shi-Ping Yang, Jian-Xian Chen, Jing-Ying Xu, Jian Lei, San-Gang Wu, Juan Zhou
Summary: The study suggests that primary debulking surgery may be the optimal procedure for the majority of advanced epithelial ovarian cancer patients, aiming for complete resection of all residual diseases.
Article
Oncology
Estelle Turrel, Nicolas Chopin, Pierre Meeus, Anna Blache, Isabelle Ray-Coquard, Olivier Tredan, Isabelle Treilleux, Coralie Ebring, Mellie Heinemann, Lea Rossi
Summary: Cytoreductive surgery is crucial in the treatment of ovarian cancer, but it may lead to significant morbidity. However, achieving no residual tumor (CC-0) has been shown to improve prognosis. This study found that postoperative pathological analysis often does not overestimate peritoneal involvement, and the potential surgical morbidity associated with peritoneal resection in IDS is acceptable.
Article
Oncology
Francois Kraus, Houssein El Hajj, Marie-Cecile Le Deley, Othman Aissaoui, Bertrand Gachon, Annick Chevalier, Cyril Abdeddaim, Anne-Sophie Lemaire, Mariem Ben Haj Amor, Dienabou Sylla, Eric Leblanc, Fabrice Narducci, Delphine Hudry
Summary: This study evaluated the comparability of patients treated with primary cytoreduction and neoadjuvant chemotherapy for advanced stages high grade serous ovarian carcinoma. The study found higher CA125 levels, PCI scores, and rates of stage IV in the NACT group. There were no significant differences in complication rates between the two groups.
Review
Oncology
Siyuan Zeng, Yongai Yu, Yuemei Cui, Bing Liu, Xianyu Jin, Zhengyan Li, Lifeng Liu
Summary: This study compared the outcomes of minimally invasive surgery (MIS) and open laparotomy for interval debulking surgery (IDS) in patients with ovarian cancer (OC) after neoadjuvant chemotherapy. The results showed no significant difference in overall survival between the MIS and open laparotomy groups, but MIS was associated with significantly higher progression-free survival and shorter hospital stays. There were no significant differences in tumor debulking, residual disease, and postoperative complications between the two groups.
FRONTIERS IN ONCOLOGY
(2022)
Article
Reproductive Biology
Xingyu Liu, Yingjun Zhao, Xiaofei Jiao, Yang Yu, Ruyuan Li, Shaoqing Zeng, Jianhua Chi, Guanchen Ma, Yabing Huo, Ming Li, Zikun Peng, Jiahao Liu, Qi Zhou, Dongling Zou, Li Wang, Qingshui Li, Jing Wang, Shuzhong Yao, Youguo Chen, Ding Ma, Ting Hu, Qinglei Gao
Summary: A retrospective real-world study was conducted on 658 patients with advanced epithelial ovarian cancer in China to investigate the prognostic relevance of the time to interval debulking surgery (TTS) and the time to postoperative adjuvant chemotherapy (TTC). The delays of TTS and TTC after the completion of neoadjuvant chemotherapy (NACT) were found to have adverse impacts on overall survival (OS) but no impacts on progression-free survival (PFS).
JOURNAL OF OVARIAN RESEARCH
(2023)
Article
Oncology
Vasileios Mitsopoulos, Anni Innamaa, Jonathan Lippiatt, Sarah Collins, Ioannis Biliatis
Summary: Advanced ovarian cancer patients receiving neoadjuvant chemotherapy (NACT) experience differences in pattern and timing of recurrence compared to patients undergoing primary debulking surgery (PDS). NACT patients have a higher recurrence rate, with more frequent intra-abdominal and multi-site recurrences.
ANTICANCER RESEARCH
(2022)
Article
Oncology
Tatsuya Ishiguro, Ai Sato, Hirokazu Ohata, Yoshinori Ikarashi, Ryou-u Takahashi, Takahiro Ochiya, Masayuki Yoshida, Hitoshi Tsuda, Takashi Onda, Tomoyasu Kato, Takahiro Kasamatsu, Takayuki Enomoto, Kenichi Tanaka, Hitoshi Nakagama, Koji Okamoto
Article
Oncology
Tomoyasu Kato, Atsuo Takashima, Takahiro Kasamatsu, Kenichi Nakamura, Junki Mizusawa, Toru Nakanishi, Nobuhiro Takeshima, Shoji Kamiura, Takashi Onda, Toshiyuki Sumi, Masashi Takano, Hidekatsu Nakai, Toshiaki Saito, Kiyoshi Fujiwara, Masatoshi Yokoyama, Hiroaki Itamochi, Kazuhiro Takehara, Harushige Yokota, Tomoya Mizunoe, Satoru Takeda, Kenzo Sonoda, Tanri Shiozawa, Takayo Kawabata, Shigeru Honma, Haruhiko Fukuda, Nobuo Yaegashi, Hiroyuki Yoshikawa, Ikuo Konishi, Toshiharu Kamura
GYNECOLOGIC ONCOLOGY
(2015)
Review
Oncology
Takahide Arimoto, Kei Kawana, Katsuyuki Adachi, Yuji Ikeda, Kazunori Nagasaka, Tetsushi Tsuruga, Aki Yamashita, Katsutoshi Oda, Mitsuya Ishikawa, Takahiro Kasamatsu, Takashi Onda, Ikuo Konishi, Hiroyuki Yoshikawa, Nobuo Yaegashi
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2015)
Review
Oncology
Koji Matsumoto, Takashi Onda, Nobuo Yaegashi
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2015)
Article
Biology
Itaru Soda, Hiromichi Ishiyama, Shigemitsu Ono, Kouji Takenaka, Masahide Arai, Tsutomu Arai, Haruko Iwase, Akane Sekiguchi, Shogo Kawakami, Shouko Komori, Takashi Onda, Kazushige Hayakawa
JOURNAL OF RADIATION RESEARCH
(2015)
Article
Oncology
Hidemichi Watari, Hiroshi Katayama, Taro Shibata, Kimio Ushijima, Toyomi Satoh, Takashi Onda, Daisuke Aoki, Haruhiko Fukuda, Nobuo Yaegashi, Noriaki Sakuragi
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2017)
Article
Oncology
Mitsuya Ishikawa, Takahiro Kasamatsu, Hitoshi Tsuda, Masaharu Fukunaga, Atsuhiko Sakamoto, Tsunehisa Kaku, Toru Nakanishi, Yoko Hasumi, Takashi Iwata, Tsukasa Baba, Takayoshi Nogawa, Wataru Kudaka, Hiroshi Kaneda, Shigemitsu Ono, Fumitaka Saito, Yoshimi Taniguchi, Satoshi Okada, Mika Mizuno, Takashi Onda, Nobuo Yaegashi
GYNECOLOGIC ONCOLOGY
(2018)
Article
Oncology
Shinichi Togami, Yuko Sasajima, Takateru Oi, Mitsuya Ishikawa, Takashi Onda, Shun-Ichi Ikeda, Tomoyasu Kato, Hitoshi Tsuda, Takahiro Kasamatsu
Article
Oncology
Takashi Uehara, Takashi Onda, Shinichi Togami, Tsukuru Amano, Michihiro Tanikawa, Morio Sawada, Shun-ichi Ikeda, Tomoyasu Kato, Takahiro Kasamatsu
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2012)
Article
Oncology
Futoshi Kunieda, Takahiro Kasamatsu, Takahide Arimoto, Takashi Onda, Takafumi Toita, Taro Shibata, Haruhiko Fukuda, Toshiharu Kamura
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2015)
Article
Oncology
Yuki Tazo, Atsuko Hara, Takashi Onda, Makoto Saegusa
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2014)
Article
Obstetrics & Gynecology
Shun-ichi Ikeda, Kenichi Yoshimura, Takashi Onda, Takahiro Kasamatsu, Tomoyasu Kato, Mitsuya Ishikawa, Yuko Sasajima, Hitoshi Tsuda
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
(2012)
Article
Oncology
Yuzuru Niibe, Takashi Onda, Keitaro Matsuo, Yusuke Inoue, Kazushige Hayakawa
ANTICANCER RESEARCH
(2017)
Article
Oncology
H. Yamashita, Y. Niibe, K. Okuma, M. Omori, Y. Inoue, T. Onda, K. Nakagawa, K. Hayakawa
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY
(2014)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)